Homologous Recombination Deficient Diagnosis and PARP Inhibitor Therapy | Webinar | Ambry Genetics

This webinar will introduce the audience to the role of genomic instability in cancer development and progression and how inherited cancers fit into this view. Specifically, we will learn how loss of function in BRCA1, BRCA2, and related genes contribute to genomic instability and how that phenotype can drive acquisition of cancer hallmarks. Loss of function in BRCA1 or BRCA2 are associated with a phenotype known as “Homologous Recombination Deficiency” or HRD, this phenotype leaves cells more vulnerable to DNA damaging agents and is currently being exploited by a class of targeted therapies – PARP inhibitors. We’ll learn how these agents work and go over some of the evidence in their favor. Lastly, we’ll explore diagnostic approaches to identifying individuals with HRD.

Presented by:
Brady Culver, PhD | Presenter
Director, R&D- Assay Development, Ambry Genetics

Brady P Culver has been with Ambry Genetics since January of 2019, where he is Director of Assay Development. Brady and his group have led or supported high impact operational efficiency projects in the clinical lab in support of higher volume germline testing demands. Additionally, they led development of a clinical trial assay for Clovis Oncology designed to identify patients likely to benefit from PARP inhibitor treatment using cutting edge methods and geared towards hypothetical patient populations. Notably, prior to joining Ambry Brady was an early employee and key member of ArcherDx R&D team, where he led that company’s library chemistry development. Brady holds a PhD in Molecular Biology from the University of Colorado and a BS in Physiology from University of California, San Diego. Brady is an author on 10 peer reviewed publications and is primary inventor on 5 patents, 4 applications and one granted.

Sarah Campian, MS, CGC | Moderator
Genomic Science Liaison, Ambry Genetics

Sarah Campian joined Ambry Genetics in 2018 as the Oncology Genetic Specialist for the Great Lakes territory. She previously worked as a clinical genetic counselor at the Grosfeld Cancer Genetics Center at Beaumont Health. Her research interests include Lynch syndrome and identification of gene mutation carriers in minority populations. Sarah received her Bachelors of Science degree in Biology from Saginaw Valley State University. She earned her Masters of Science degree in Genetic Counseling from Wayne State University and is certified by the American Board of Genetic Counseling.